Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
Condition(s):Lung CancerLast Updated:April 24, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Lung CancerLast Updated:April 24, 2017Completed
Condition(s):Anal Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Lung CancerLast Updated:July 20, 2012Completed
Condition(s):Pulmonary HypertensionLast Updated:November 1, 2012Completed
Condition(s):Pulmonary HypertensionLast Updated:October 23, 2017Completed
Condition(s):Copd; Fall PatientsLast Updated:May 5, 2022Suspended
Condition(s):Cardiovascular DiseasesLast Updated:April 10, 2014Unknown status
Condition(s):Chronic Obstructive Pulmonary Disease With Acute Exacerbation, UnspecifiedLast Updated:June 14, 2019Terminated
Condition(s):Chronic Obstructive Pulmonary DiseaseLast Updated:June 18, 2020Unknown status
Condition(s):Non Small Cell Lung Cancer; Pulmonary MetastasesLast Updated:June 5, 2008Completed
Condition(s):Pulmonary DiseaseLast Updated:November 30, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.